Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
280Bio General Information
The company’s lead candidate TEB‑17231 (YL‑17231), an oral pan-RAS inhibitor targeting multiple RAS mutations including those resistant to existing therapies, is in Phase I clinical trials for advanced solid tumors. Preclinical data show potent inhibition of tumor proliferation across various RAS alterations. Additional candidates are advancing through preclinical and IND-enabling studies.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
South San Francisco/San Francisco Bay Area, California
United States
United States
Drug Pipeline
TEB-17231
Phase 1Key Partnerships
The University of Texas MD Anderson Cancer Center (“MDACC”): strategic collaboration on oncology agents’ development and clinical trials in the US/EU.
280Bio Funding
No funding data available
To view 280Bio's complete valuation and funding history, request access »